Lower Lilly Earnings the Shape of Things to Come
Eli Lilly announced its first quarter financial results on April 19. But even though the company trumpeted a global revenue growth rate of 9 percent—$5.49 billion, compared to Q1 2009’s $5.05...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
AZ's Seroquel Battle with FDA: A Mark of Desperation?
By Ana Nicholls, Healthcare Analyst at the Economist Intelligence Unit. Is it a mark of desperation? UK-based pharma company AstraZeneca has resorted to suing the US Food and Drug Administration in a...
View ArticleThe Curious Case Of AstraZeneca v. ACE
by Mike Kelly and Andrew Dupre Insurance contracts are a language game that must be played very carefully, as AstraZeneca learned. From 2003 to 2012, AstraZeneca Plc was locked in one of the largest...
View Article
